TY - JOUR
T1 - Germline Testing in Prostate Cancer
T2 - When and Who to Test
AU - Sokolova, Alexandra O.
AU - Cheng, Heather H.
N1 - Publisher Copyright:
© 2021 UBM Medica Healthcare Publications. All rights reserved.
PY - 2021
Y1 - 2021
N2 - The results of multiple studies have shown that a substantial proportion of men with advanced prostate cancer carry germline DNA repair mutations. Germline testing in prostate cancer may inform treatment decisions and consideration for clinical trials. There are 2 FDA approved PARP inhibitors (PARPi), olaparib (Lynparza) and rucaparib (Rubraca), for the treatment of advanced prostate cancer with DNA repair deficiency. Increasing demand for germline testing in prostate cancer and a shortage of genetic counselors have created a need for alternative care models and encouraged oncologists to take a more active role in performing germline testing. This article summarizes recommendations for germline testing in prostate cancer and describes care models for providing counseling and testing.
AB - The results of multiple studies have shown that a substantial proportion of men with advanced prostate cancer carry germline DNA repair mutations. Germline testing in prostate cancer may inform treatment decisions and consideration for clinical trials. There are 2 FDA approved PARP inhibitors (PARPi), olaparib (Lynparza) and rucaparib (Rubraca), for the treatment of advanced prostate cancer with DNA repair deficiency. Increasing demand for germline testing in prostate cancer and a shortage of genetic counselors have created a need for alternative care models and encouraged oncologists to take a more active role in performing germline testing. This article summarizes recommendations for germline testing in prostate cancer and describes care models for providing counseling and testing.
UR - http://www.scopus.com/inward/record.url?scp=85120149364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120149364&partnerID=8YFLogxK
U2 - 10.46883/ONC.2021.3510.0645
DO - 10.46883/ONC.2021.3510.0645
M3 - Review article
C2 - 34669358
AN - SCOPUS:85120149364
SN - 0890-9091
VL - 35
SP - 645
EP - 653
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
IS - 10
ER -